
Breast cancer glossary of terms
Here are definitions of some common terms associated with breast cancer.
Cancer
Carcinoma
Cell
Chemotherapy
Estrogen receptor
First-line
HER2
Hormone therapy
Intravenous
Metastatic (also known as advanced cancer)
Monotherapy
Oncologist
Overall response rate
Radiation therapy
Stage I
Stage II
Stage III
Stage IV
Targeted therapy
Time to progression
Tumor
Cancer
Cancer is actually a group of diseases. All forms of cancer cause cells in the body to change and grow out of control. Most types of cancer cells form a lump called a tumor, which can invade and destroy healthy tissue. Cells from a cancerous or malignant tumor can break away and travel to other parts of the body. They can continue to grow there. Some cancers, such as blood cancers, do not form tumors. Not all tumors are cancer. These tumors are called benign, because they do not grow and spread like cancer does. They are usually not a threat to life.32
Carcinoma
A malignant tumor that begins in the lining layer (epithelial cells) of organs. At least 80% of all cancers are carcinomas, and almost all breast cancers are
carcinomas.32
Cell
The basic unit of which all living things are made. The processes that control formation of new cells and death of old cells are disrupted in cancer.32
Chemotherapy
Systemic treatment with drugs to destroy cancer cells. It is often administered intravenously and can be given as single therapy or in combination with multiple drugs at once. Chemotherapy can be administered concurrently or sequentially with other treatments and in addition to surgery or radiation to treat cancer when it has spread, when it has come back (recurred), or when there is a strong chance that it could recur.32
Estrogen receptor
A protein that is found inside some tumor cells. When estrogen attaches to the receptor, certain changes stimulate growth in the cell. As a result, treatments that prevent hormones from attaching to these receptors may stop tumor growth.32
First-line
The initial therapy for the condition being treated.33
HER2
This receptor is present in very small amounts on the outer surface of normal breast cells. About 25% to 30% of breast cancers have too much of this receptor. Cancers that have too much of this receptor tend to be more aggressive. Also referred to as ErbB2.32
Hormone therapy
Treatment with drugs that interfere with hormone production or hormone action.32
Intravenous
A method of supplying fluids or medications using a needle inserted in a
vein.32
Metastatic (also known as advanced cancer)
A general term describing stages of cancer in which the disease has spread from the primary site to other parts of the body. When the cancer has spread only to the surrounding areas, it is called locally advanced. If it has spread to distant parts of the body, it is called metastatic.32
Monotherapy
The use of a single drug to treat a disease.34
Oncologist
A doctor with special training in the diagnosis and treatment of cancer.32
Overall response rate
The percentage of people showing either a partial response or a complete (full) response to the given treatment. A partial response refers to the observation of tumor size decreasing (shrinking) by clinical (physical exam) or radiographic (X-rays, CT, MRI, PET, Bone Scan, etc.) assessment, and complete response refers to the complete disappearance of the tumor by clinical or radiographic assessments.34
Radiation therapy
Treatment with high-energy rays (such as X-rays) to kill cancer cells. The radiation may come from outside of the body (external radiation) or from radioactive materials placed directly in the tumor (brachytherapy or internal radiation). Radiation therapy may be used to reduce the size of a cancer before surgery, to destroy any remaining cancer cells after surgery, or in some cases, as the main treatment. In advanced cancer cases, it may also be used to provide symptomatic relief.32
Stage I
Early-stage breast cancer where the tumor is less than two centimeters across and hasn't spread beyond the breast.35
Stage II
Early-stage breast cancer where the tumor is either less than two centimeters across and has spread to the lymph nodes under the arm on the same side as the affected breast; or the tumor is between two to five centimeters (with or without spread to the lymph nodes under the arm) on the same side as the affected breast; or the tumor is greater than five centimeters and hasn't spread outside the breast.35
Stage III
Locally advanced breast cancer where the tumor is greater than five centimeters across and has spread to the lymph nodes under the arm; or the cancer is extensive in the underarm lymph nodes; or the cancer has spread to lymph nodes near the breastbone or to other tissues near the breast.35
Stage IV
Metastatic breast cancer where the cancer has spread outside the breast to other organs in the body.35
Targeted therapy
A type of cancer treatment that is intended to attack specific cancer cells without harming normal cells.32
Time to progression
Time to progression, or TTP, is the time between when a patient enters the study and the time that either her disease progresses (advances) or the patient dies due to breast cancer prior to progression.34
Tumor
An abnormal lump or mass of tissue. Tumors can be benign (not cancerous) or malignant (cancerous).32
Ask the Experts
Get answers to your questions about TYKERB.
Get More Information
Get updates from www.TYKERB.com.
Get support from Tykerb® CARES
Indication
TYKERB is indicated in combination with Xeloda® (capecitabine) for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 and who have received prior therapy including an anthracycline, a taxane, and Herceptin® (trastuzumab).
Important Safety Information
Some women may develop liver damage while taking TYKERB. The cause of this damage is not known. In some cases, liver damage may be severe and may cause death. Your doctor should test your liver before and during treatment with TYKERB to check for signs of liver damage. You should contact your doctor if you have itching, yellow eyes or skin, dark urine, pain in your right upper side of your belly or feel very tired. If you develop liver damage during your treatment, your doctor may tell you to stop taking TYKERB. Before taking TYKERB, tell your doctor if you have liver problems. You may need a lower dose of TYKERB.
Before taking TYKERB, tell your doctor if you have heart problems. As with other treatments for HER2-positive advanced or metastatic breast cancer, there have been reports of changes in how the heart pumps blood through the body and how the heart beats. Call your doctor right away if you are short of breath, have rapid heartbeats (palpitations), or feel very tired.
Some people taking TYKERB have reported diarrhea. In some cases, diarrhea can be severe. Call your doctor right away if you have diarrhea. It is important to manage diarrhea with medicine as soon as it begins. Severe diarrhea may need to be treated with electrolytes and fluids given by mouth or by vein. Treatment with TYKERB may have to be delayed for a while or stopped completely.
If you have a dry cough or have shortness of breath, talk with your doctor. These may be signs of inflammation in the lungs.
Women should not become pregnant when taking TYKERB because the unborn baby may be harmed.
The most common side effects reported by patients taking TYKERB and Xeloda were diarrhea; vomiting; feeling sick to your stomach (nausea); feeling tired; red, painful hands and feet; and rash.
Tell your doctor about all the medicines you take, including prescription and nonprescription medicines and herbal and dietary supplements.
Because TYKERB is currently indicated to be taken with another medicine called Xeloda, be sure to talk with your doctor about any medicines and supplements that should be avoided when taking Xeloda.
Please see complete US Prescribing Information for TYKERB.
Xeloda is a registered trademark of Roche Laboratories Inc.
Herceptin is a registered trademark of Genentech, Inc.
Photos are for illustrative purposes only.




